GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Compound class:
Synthetic organic
Comment: This is an orally bioactive small molecule inhibitor of IL-17A interaction with its receptor and IL-17-mediated inflammation [1]. It is one of the compounds that are claimed in Dice Therapeutics' development pipeline. There are two named leads in their pipeline (DC-806 and DC-853 [2]) and a third unnamed lead, but as of May 2025 no name to structure(s) have been formally disclosed for these. DC-806 and DC-853 are both in phase 2 studies for plaque psoriasis.
|
|
Download 2D Structure ![]() |
|
Canonical SMILES | Download |
Isomeric SMILES | Download |
InChI standard identifier | Download |
InChI standard key | Download |
Molecular structure representations generated using Open Babel